Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07180927 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DLL3 CAR-T Therapy Targeting Brain Tumors

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Sep 10, 2025 to Jun 1, 2027v2 Show 5 more changesShow less
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Primary completion moved earlier from Dec 31, 2028 to May 31, 2028
    • Study completion moved earlier from Sep 30, 2029 to Dec 31, 2028
    • Study description expanded, about 66 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.
Trial Details
NCT Number NCT07180927
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Glioblastoma of Cerebellum
Related terms Glioblastoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov